Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542–56. https://doi.org/10.1016/j.jhep.2023.06.003.

Article  CAS  PubMed  Google Scholar 

Wei S, Wang L, Evans PC, Xu S. NAFLD and NASH: etiology, targets and emerging therapies. Drug Discov Today. 2024;29:103910. https://doi.org/10.1016/j.drudis.2024.103910.

Article  CAS  PubMed  Google Scholar 

Gan Z, Xia Y, Bin P, Zhao M, Zhou Y, Liu B, et al. Excitatory amino acid transporters support mast cell degranulation via α-KG-mediated methylation of Spp1. Cell Mol Immunol. 2026. https://doi.org/10.1038/s41423-025-01375-7.

Article  PubMed  PubMed Central  Google Scholar 

Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397:2212–24. https://doi.org/10.1016/S0140-6736(20)32511-3.

Article  CAS  PubMed  Google Scholar 

Juanola O, Martinez-Lopez S, Frances R, Gomez-Hurtado I. Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors. Int J Environ Res Public Health. 2021. https://doi.org/10.3390/ijerph18105227.

Article  PubMed  PubMed Central  Google Scholar 

Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20. https://doi.org/10.1038/nrgastro.2017.109.

Article  PubMed  Google Scholar 

Guo X, Yin X, Liu Z, Wang J. Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms232415489.

Article  PubMed  PubMed Central  Google Scholar 

Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22:63. https://doi.org/10.1186/s12902-022-00980-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nassir F. NAFLD: mechanisms, treatments, and biomarkers. Biomolecules. 2022. https://doi.org/10.3390/biom12060824.

Article  PubMed  PubMed Central  Google Scholar 

Liu S, Yao S, Yang H, Liu S, Wang Y. Autophagy: regulator of cell death. Cell Death Dis. 2023;14:648. https://doi.org/10.1038/s41419-023-06154-8.

Article  PubMed  PubMed Central  Google Scholar 

Qian H, Chao X, Williams J, Fulte S, Li T, Yang L, et al. Autophagy in liver diseases: A review. Mol Aspects Med. 2021;82:100973. https://doi.org/10.1016/j.mam.2021.100973.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xiu A, Ding Q, Li Z, Zhang C. Doxazosin attenuates liver fibrosis by inhibiting autophagy in hepatic stellate cells via activation of the PI3K/Akt/mTOR signaling pathway. Drug Des Devel Ther. 2021;15:3643–59. https://doi.org/10.2147/DDDT.S317701.

Article  PubMed  PubMed Central  Google Scholar 

Xie F, Fan J, Wang H, Song Q, Xu Y, Lan Q, et al. Macrophage TRIM21 knockout inhibits septic acute lung injury by downregulating autophagy regulator protein ubiquitination. Autophagy. 2025. https://doi.org/10.1080/15548627.2025.2519063.

Article  PubMed  PubMed Central  Google Scholar 

Zhang L, Zhang Z, Li C, Zhu T, Gao J, Zhou H, et al. S100A11 promotes liver steatosis via FOXO1-mediated autophagy and lipogenesis. Cell Mol Gastroenterol Hepatol. 2021;11:697–724. https://doi.org/10.1016/j.jcmgh.2020.10.006.

Article  CAS  PubMed  Google Scholar 

Yan L, Zhang S, Luo G, Cheng BC, Zhang C, Wang Y, et al. Schisandrin B mitigates hepatic steatosis and promotes fatty acid oxidation by inducing autophagy through AMPK/mTOR signaling pathway. Metabolism. 2022;131:155200. https://doi.org/10.1016/j.metabol.2022.155200.

Article  CAS  PubMed  Google Scholar 

Endo S, Matsunaga T, Nishinaka T. The role of AKR1B10 in physiology and pathophysiology. Metabolites. 2021. https://doi.org/10.3390/metabo11060332.

Article  PubMed  PubMed Central  Google Scholar 

Guo M, Wang T, Ge W, Ren C, Ko BC, Zeng X, et al. Role of AKR1B10 in inflammatory diseases. Scand J Immunol. 2024;100:e13390. https://doi.org/10.1111/sji.13390.

Article  CAS  PubMed  Google Scholar 

Wang Z, Pei Y, Li W, Zhang J, Liu J. Clinical value of AKR1B10 in hepatocellular carcinoma: a systematic review and meta-analysis. PLoS ONE. 2022;17:e279591. https://doi.org/10.1371/journal.pone.0279591.

Article  CAS  Google Scholar 

Jang T, Lin S, Yang Y, Lay J, Chang C, Yao C, et al. The role of AKR1B10 in lung cancer malignancy induced by sublethal doses of chemotherapeutic drugs. Cancers (Basel). 2024. https://doi.org/10.3390/cancers16132428.

Article  PubMed  PubMed Central  Google Scholar 

Wang Q, Jiang Y, Xu L, Chen J. Echinacoside hampers malignant progression of breast cancer MCF-7 cells by modulating AKR1B10/ERK signal transduction. Zhongguo Zhong Yao Za Zhi. 2023;48:744–51. https://doi.org/10.19540/j.cnki.cjcmm.20221102.702.

Article  CAS  PubMed  Google Scholar 

Yang S, Cao S, Li C, Zhang Q, Zhang B, Qiu F, et al. Berberine directly targets AKR1B10 protein to modulate lipid and glucose metabolism disorders in NAFLD. J Ethnopharmacol. 2024;332:118354. https://doi.org/10.1016/j.jep.2024.118354.

Article  CAS  PubMed  Google Scholar 

Rajak S, Gupta P, Anjum B, Raza S, Tewari A, Ghosh S, et al. Role of AKR1B10 and AKR1B8 in the pathogenesis of non-alcoholic steatohepatitis (NASH) in mouse. Biochim Biophys Acta Mol Basis Dis. 2022;1868:166319. https://doi.org/10.1016/j.bbadis.2021.166319.

Article  CAS  PubMed  Google Scholar 

Peng Y, Wang Y, Zhou C, Mei W, Zeng C. PI3K/Akt/mTOR pathway and its role in cancer therapeutics: Are we making headway? Front Oncol. 2022;12:819128. https://doi.org/10.3389/fonc.2022.819128.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ramasubbu K, Devi Rajeswari V. Impairment of insulin signaling pathway PI3K/Akt/mTOR and insulin resistance induced AGEs on diabetes mellitus and neurodegenerative diseases: a perspective review. Mol Cell Biochem. 2023;478:1307–24. https://doi.org/10.1007/s11010-022-04587-x.

Article  CAS  PubMed  Google Scholar 

Deng R, Zhou J. The role of PI3K/AKT signaling pathway in myocardial ischemia-reperfusion injury. Int Immunopharmacol. 2023;123:110714. https://doi.org/10.1016/j.intimp.2023.110714.

Article  CAS  PubMed  Google Scholar 

Shamsan E, Almezgagi M, Gamah M, Khan N, Qasem A, Chuanchuan L, et al. The role of PI3k/AKT signaling pathway in attenuating liver fibrosis: a comprehensive review. Front Med. 2024;11:1389329. https://doi.org/10.3389/fmed.2024.1389329.

Article  Google Scholar 

Ye Q, Liu Y, Zhang G, Deng H, Wang X, Tuo L, et al. Deficiency of gluconeogenic enzyme PCK1 promotes metabolic-associated fatty liver disease through PI3K/AKT/PDGF axis activation in male mice. Nat Commun. 2023;14:1402. https://doi.org/10.1038/s41467-023-37142-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang C, Tan X, Yang H, Jin L, Hong J, Zhou Y, et al. COX-2/sEH dual inhibitor alleviates hepatocyte senescence in NAFLD mice by restoring autophagy through Sirt1/PI3K/AKT/mTOR. Int J Mol Sci. 2022;23:8267. https://doi.org/10.3390/ijms23158267.

Article  CAS